Activity of AMN107, a novel aminopyrimidine inhibitor of Bcr-Abl, in imatinib-resistant Bcr-Abl positive lymphoid malignancies.

被引：0
|
作者：
Ottmann, O
Giles, F
Wassmann, B
Hochhaus, A
Rae, P
Beran, M
Albitar, M
Alland, L
Dugan, M
Kantarjian, H
机构：
[1] Univ Frankfurt, D-6000 Frankfurt, Germany
[2] Univ Texas, MD Anderson Canc Ctr, Houston, TX 77030 USA
[3] Univ Heidelberg, D-6800 Mannheim, Germany
[4] Novartis Pharmaceut Corp, E Hanover, NJ USA
[5] Quest Diagnost, San Juan Capistrano, CA USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2005年 / 23卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：195S / 195S
页数：1
相关论文
共 50 条
  • [21] Generation of resistance cell lines to AMN107, a new inhibitor of BCR-ABL and its effects on cell lines sensitive and resistant to imatinib.
    Mahon, FX
    Lagarde, V
    Manley, PW
    Pasquet, JM
    Turcq, B
    Reiffers, J
    BLOOD, 2004, 104 (11) : 251B - 251B
  • [22] Identification of BCR-ABL point mutations conferring resistance to the Abl kinase inhibitor AMN107 (nilotinib) by a random mutagenesis study
    Ray, Arghya
    Cowan-Jacob, Sandra W.
    Manley, Paul W.
    Mestan, Juergen
    Griffin, James D.
    BLOOD, 2007, 109 (11) : 5011 - 5015
  • [23] Abnormalities in glucose uptake and metabolism in imatinib-resistant Bcr-Abl positive cells.
    Serkova, Natalie J.
    Kominsky, Douglas J.
    Brown, Jaimi L.
    Miljus, Jelena
    Boros, Laszlo G.
    Eckhardt, Gail S.
    Melo, Junin V.
    BLOOD, 2006, 108 (11) : 662A - 662A
  • [24] AMN107: Efficacy of the selective Bcr-Abl tyrosine kinase inhibitor in a murine model of chronic myelogenous leukemia
    Jensen, Michael R.
    Bruggen, Josef
    Dilea, Clifford
    Mestan, Jurgen
    Manley, Paul W.
    CANCER RESEARCH, 2006, 66 (08)
  • [25] A Small Molecule Inhibitor, OGP46, Is Effective against Imatinib-Resistant BCR-ABL Mutations via the BCR-ABL/JAK-STAT Pathway
    Wei, Liuya
    Yang, Yang
    Gupta, Pranav
    Wang, Aihong
    Zhao, Min
    Zhao, Yao
    Qu, Mei
    Ke, Yu
    Liu, Ying
    Liu, Hong-Min
    Xu, Xin
    Sun, Yanli
    Chen, Zhe-Sheng
    Hu, Zhenbo
    MOLECULAR THERAPY-ONCOLYTICS, 2020, 18 : 137 - 148
  • [26] Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is active in patients with imatinib-resistant or -intolerant accelerated-phase chronic myelogenous leukemia
    le Coutre, Philipp
    Ottmann, Oliver G.
    Giles, Francis
    Kim, Dong-Wook
    Cortes, Jorge
    Gattermann, Norbert
    Apperley, Jane F.
    Larson, Richard A.
    Abruzzese, Elisabetta
    O'Brien, Stephen G.
    Kuliczkowski, Kazimierz
    Hochhaus, Andreas
    Mahon, Francois-Xavier
    Saglio, Giuseppe
    Gobbi, Marco
    Kwong, Yok-Lam
    Baccarani, Michele
    Hughes, Timothy
    Martinelli, Giovanni
    Radich, Jerald P.
    Zheng, Ming
    Shou, Yaping
    Kantarjian, Hagop
    BLOOD, 2008, 111 (04) : 1834 - 1839
  • [27] Bcr-Abl resistance screening predicts a limited spectrum of point mutations to be associated with clinical resistance to the Abl kinase inhibitor AMN107
    von Bubnoff, N
    Saenger, J
    Manley, PW
    Mestan, J
    Peschel, C
    Duyster, J
    BLOOD, 2005, 106 (11) : 561A - 562A
  • [28] Inhibition of Bcr-Abl kinase activity with imatinib induces poly (ADP) ribosylation in Bcr-Abl positive hematopoietic cells.
    Moehring, A
    van der Kuip, H
    Wohlbold, L
    Duyster, J
    Aulitzky, WE
    BLOOD, 2003, 102 (11) : 202B - 202B
  • [29] InCML progenitors, AMN107 is more effective than imatinib in inhibiting Bcr-Abl tyrosine kinase activity but not in inducing growth inhibition
    Konig, H.
    Holtz, M.
    Modi, H.
    Manley, P. W.
    Holyoake, T.
    Forman, S. J.
    Bhatia, R.
    EXPERIMENTAL HEMATOLOGY, 2006, 34 (09) : 55 - 55
  • [30] Structural biology guided optimization of tyrosine kinase inhibitors:: AMN107 a selective and potent Bcr-Abl inhibitor.
    Manley, PW
    Breitenstein, W
    Brüggen, J
    Cowan-Jacob, SW
    Furet, P
    Griffin, JD
    Mestan, J
    Meyer, T
    Weisberg, E
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2005, 229 : U163 - U163
12345